Daily Cosmetic Research Analysis
Three impactful studies in cosmetic medicine span perioperative analgesia, sensitive skin neurovascular modulation, and access to effective topical anesthesia. A randomized trial shows methylene blue prolongs serratus anterior plane block analgesia after prosthetic breast augmentation. Two dermatologic RCTs demonstrate a neurovascular-targeted moisturizer improves sensitive skin endpoints and a generic lidocaine/tetracaine cream is equivalent to Pliaglis for fractional laser analgesia.
Summary
Three impactful studies in cosmetic medicine span perioperative analgesia, sensitive skin neurovascular modulation, and access to effective topical anesthesia. A randomized trial shows methylene blue prolongs serratus anterior plane block analgesia after prosthetic breast augmentation. Two dermatologic RCTs demonstrate a neurovascular-targeted moisturizer improves sensitive skin endpoints and a generic lidocaine/tetracaine cream is equivalent to Pliaglis for fractional laser analgesia.
Research Themes
- Regional anesthesia optimization in cosmetic breast surgery
- Neurovascular hyper-reactivity targeting in sensitive skin
- Equivalence of topical anesthetics for fractional laser procedures
Selected Articles
1. Serratus Anterior Plane Block with Methylene Blue and Ropivacaine for analgesia in Prosthetic Breast Augmentation: A Randomized Controlled Trial.
In a double-blind randomized trial of 72 women undergoing axillary prosthetic breast augmentation, serratus anterior plane block improved early postoperative pain. Adding methylene blue to ropivacaine did not improve pain at 6 hours but produced significantly lower VAS scores at 24, 48, and 72 hours versus ropivacaine alone, indicating prolonged analgesia.
Impact: Provides Level I evidence for a low-cost adjuvant that prolongs regional anesthesia after cosmetic breast surgery. Could meaningfully reduce postoperative opioid needs and improve recovery.
Clinical Implications: Consider adding methylene blue to ropivacaine for serratus plane blocks in axillary breast augmentation to extend analgesia through 72 hours, potentially reducing rescue analgesics.
Key Findings
- SAPB improved postoperative pain control within 24 hours compared with standard care.
- Ropivacaine + methylene blue yielded significantly lower VAS scores than ropivacaine alone at 24, 48, and 72 hours (P < 0.05).
- No baseline imbalances across groups in age, BMI, implant brand, size, or type; no early (6 h) advantage with methylene blue.
Methodological Strengths
- Double-blind randomized controlled design with independent outcome assessors
- Prospective registration and predefined timepoints (6, 24, 48, 72 hours) with standard analgesic regimen across groups
Limitations
- Single-center trial with modest sample size (n=72) limits generalizability
- Safety outcomes and adverse events were not detailed beyond efficacy timepoints
Future Directions: Confirm in multicenter trials, evaluate dose-response for methylene blue, assess opioid-sparing effects and safety (e.g., skin staining, neurotoxicity) and broader cosmetic procedures.
BACKGROUND: Pain is a prominent symptom in prosthetic breast augmentation via axillary incision and persists throughout hospitalization. However, routine analgesia is not always effective for all patients. Duration of regional block with ropivacaine is also limited. The objective is to evaluate whether the combination of methylene blue and ropivacaine via serratus anterior plane block provides superior long-lasting analgesia compared to ropivacaine alone in prosthetic breast augmentation. METHODS: This double-blind, single-center, randomized controlled trial enrolled 72 female patients, who were randomly and equally assigned to the control group, the ropivacaine group and the ropivacaine + methylene blue group during surgery. A standard postoperative analgesic regimen was administered to all patients. The visual analogue scale (VAS) was employed to assess pain scores, which were observed and recorded at 6, 24, 48 and 72 hours postoperatively by two well-trained, independent investigators. RESULTS: No statistically significant differences were observed in age (P = 0.200), BMI (P = 0.200), prosthesis brand (P = 0.764), size (P = 0.580) or type (P = 0.260) among the three groups. The study demonstrated that serratus anterior plane block significantly improves postoperative pain management within 24 hours. Furthermore, the ropivacaine + methylene blue group showed no advantages over ropivacaine group at 6 hours postoperatively, while it had a better VAS score than the ropivacaine group 24, 48 and 72 hours postoperatively, which were statistically significant differences (P < 0.05). CONCLUSIONS: The analgesic effect of methylene blue and ropivacaine in serratus anterior plane block has a longer duration than ropivacaine alone in prosthetic breast augmentation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I. TRIAL REGISTRATION: ChiCTR2500097610.
2. Clinical Observation of a Novel Moisturizing Cream for Reducing Neurovascular Hyper-Reactivity in Sensitive Skin.
In a randomized double-blind split-face trial (n=35), both the experimental and control creams improved sensitive skin symptoms and barrier parameters. The experimental cream uniquely reduced capsaicin pain (CAT) and increased current perception thresholds (CPT), and showed greater improvements in pruritus, erythema, and TEWL, indicating neurovascular hyper-reactivity modulation.
Impact: Demonstrates a targeted approach to sensitive skin by objectively modulating neurocutaneous endpoints (CAT, CPT), moving beyond barrier repair alone.
Clinical Implications: For patients with sensitive skin refractory to standard moisturizers, consider formulations that demonstrate reductions in CAT and increases in CPT alongside TEWL improvement.
Key Findings
- Both experimental and control creams improved symptoms/signs, increased stratum corneum hydration, and reduced TEWL, LAST, and DLQI.
- The experimental cream showed superior improvements in pruritus, erythema, and TEWL versus control.
- Only the experimental cream reduced capsaicin pain test (CAT) scores and increased current perception threshold (CPT), indicating reduced neurovascular hyper-reactivity.
Methodological Strengths
- Randomized, double-blind, self-controlled (split-face) design minimizing inter-individual variability
- Multimodal outcomes including objective neurocutaneous measures (CPT, CAT) and biophysical parameters
Limitations
- Small sample size and single-country study limit generalizability
- Short duration (28 days) and product composition details not fully elaborated
Future Directions: Larger, longer multicenter RCTs with mechanistic biomarkers and head-to-head comparisons versus standard-of-care sensitive skin products.
BACKGROUND: Sensitive skin is a syndrome characterized by unpleasant sensations in response to external stimuli. Its pathogenesis is linked to impaired skin barrier function, leading to neurovascular hyper-reactivity and inflammation. While topical functional skincare products are known to repair sensitive skin, there are limited reports on products specifically targeting the reduction of neurovascular hyper-reactivity. OBJECTIVE: To evaluate the efficacy and safety of a novel cream in improving neurovascular hyper-reactivity and subjective symptoms in sensitive skin. METHODS: This randomized, double-blind, self-controlled trial included 35 participants. One side of the face was treated with experimental cream (Group A) and the other with control cream (Group B), applied twice daily for 28 days. Follow-up assessments were performed on Day 0, Day 7, Day 14, and Day 28, with 28-day post-trial safety monitoring. Evaluations included clinical evaluation by physician, participant self-assessment of symptoms, measurements of skin physiological parameters and current perception threshold (CPT), lactic acid stinging test (LAST), capsaicin pain test (CAT), product usage experience, and participant tolerance. RESULTS: The experimental cream demonstrates good safety and user experience. Both the experimental and control creams effectively improve symptoms and signs of sensitive skin, increase SC hydration, and lower TWEL, LAST, and DLQI scores. Additionally, the experimental cream outperforms the control cream in improving pruritus, erythema, and TWEL. The experimental cream also has the unique advantage of reducing CAT scores and increasing CPT. CONCLUSION: The new cream has good safety and can effectively reduce neurovascular hyper-reactivity, alleviating symptoms in individuals with sensitive skin.
3. Efficacy and Safety of Combined Topical Lidocaine and Tetracaine Cream for Facial Fractional Laser Resurfacing Compared With Its Reference Product in Chinese Adults: A Multicenter, Randomized, Double-Blind Phase 3 Study.
In a multicenter randomized double-blind split-face phase 3 trial (n=284), a 7% lidocaine/7% tetracaine generic cream (CU-30101) was equivalent to Pliaglis for analgesia during facial fractional laser resurfacing. Satisfaction, local tolerability, and safety were favorable and comparable for both products.
Impact: Confirms therapeutic equivalence of a generic topical anesthetic to a widely used reference, potentially improving affordability and access for cosmetic laser procedures.
Clinical Implications: CU-30101 can be used interchangeably with Pliaglis for facial fractional laser analgesia, supporting formulary flexibility without compromising efficacy or safety.
Key Findings
- Mean VAS scores were similar between CU-30101 (35.3 ± 24.51) and Pliaglis (37.3 ± 24.17).
- The 95% CI for VAS difference (-3.78 to -0.13) fell within the predefined equivalence margin (±4.7), confirming efficacy equivalence.
- Both products had high participant and investigator satisfaction and favorable local tolerability and safety.
Methodological Strengths
- Multicenter, randomized, double-blind, split-face equivalence design with predefined margin
- Both ITT-like overall and per-protocol analyses supported equivalence
Limitations
- Population limited to Chinese adults; generalizability to other ethnicities and skin types requires confirmation
- Peri-procedural assessment without long-term follow-up or cost-effectiveness analysis
Future Directions: Evaluate performance across diverse Fitzpatrick skin types, other laser modalities, and real-world cost and workflow impacts.
BACKGROUND: As a potentially effective anesthetic, CU-30101 is comprised of 7% lidocaine and 7% tetracaine and is a generic drug of Pliaglis. This study aimed to investigate the equivalence between CU-30101 and Pliaglis as topical anesthetics for fractional laser. METHODS: This Phase 3 trial recruited Chinese adults scheduled for facial fractional laser resurfacing. Participants were randomized to receive opposite treatment sequences of CU-30101 and Pliaglis on contralateral sides of the face prior to laser application. Visual Analog Scale (VAS), participant and investigator satisfaction ratings, local tolerability, and safety were assessed. RESULTS: Two hundred eighty-four participants completed the study, with mean VAS scores of 35.3 ± 24.51 for CU-30101 and 37.3 ± 24.17 for Pliaglis. The 95% confidence interval of -3.78 to -0.13 for the VAS difference laid within the predefined equivalence margin of ±4.7, confirming equivalence in efficacy. The results in the per-protocol set further corroborated the equivalence. Both participants and investigators expressed consistently high satisfaction with CU-30101 and Pliaglis. Furthermore, both treatments were well tolerated and exhibited favorable safety profiles. CONCLUSION: This study demonstrated the equivalent efficacy of CU-30101 to its reference product, Pliaglis, among Chinese adults undergoing facial fractional laser resurfacing. CU-30101 showed commendable local tolerability and safety profiles, consistent with those of Pliaglis.